OBJECTIVE: The aim was to investigate the white matter abnormalities of drug-naïve patients with obsessive-compulsive disorder (OCD) using diffusion tensor-imaging and the white matter changes in the patients after pharmacotherapy. METHOD: Thirteen drug-naïve OCD patients and 13 age- and sex-matched healthy comparison subjects were examined using diffusion tensor-imaging and structural magnetic resonance imaging. Measurements were made in OCD patients before and after 12 weeks of citalopram treatment. RESULTS: Compared with controls, the drug-naïve OCD patients showed significant increases in fractional anisotropy (FA) in the corpus callosum, the internal capsule and white matter in the area superolateral to the right caudate. The increases in FA were mostly no longer observed in patients after 12 weeks of treatment compared with controls. CONCLUSION: Our findings suggest that white matter alterations are associated with the pathophysiology of OCD, and the abnormalities may be partly reversible with pharmacotherapy.
OBJECTIVE: The aim was to investigate the white matter abnormalities of drug-naïve patients with obsessive-compulsive disorder (OCD) using diffusion tensor-imaging and the white matter changes in the patients after pharmacotherapy. METHOD: Thirteen drug-naïve OCDpatients and 13 age- and sex-matched healthy comparison subjects were examined using diffusion tensor-imaging and structural magnetic resonance imaging. Measurements were made in OCDpatients before and after 12 weeks of citalopram treatment. RESULTS: Compared with controls, the drug-naïve OCDpatients showed significant increases in fractional anisotropy (FA) in the corpus callosum, the internal capsule and white matter in the area superolateral to the right caudate. The increases in FA were mostly no longer observed in patients after 12 weeks of treatment compared with controls. CONCLUSION: Our findings suggest that white matter alterations are associated with the pathophysiology of OCD, and the abnormalities may be partly reversible with pharmacotherapy.
Authors: Omid Kohannim; Neda Jahanshad; Meredith N Braskie; Jason L Stein; Ming-Chang Chiang; April H Reese; Derrek P Hibar; Arthur W Toga; Katie L McMahon; Greig I de Zubicaray; Sarah E Medland; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Paul M Thompson Journal: Neuropsychopharmacology Date: 2012-04-18 Impact factor: 7.853
Authors: Chadi G Abdallah; Cheuk Y Tang; Sanjay J Mathew; Jose Martinez; Patrick R Hof; Tarique D Perera; Dikoma C Shungu; Jack M Gorman; Jeremy D Coplan Journal: Neurosci Lett Date: 2010-04-03 Impact factor: 3.046
Authors: Joaquim Radua; Mar Grau; Odile A van den Heuvel; Michel Thiebaut de Schotten; Dan J Stein; Erick J Canales-Rodríguez; Marco Catani; David Mataix-Cols Journal: Neuropsychopharmacology Date: 2014-01-10 Impact factor: 7.853
Authors: Suzan Maleki; Yann Chye; Xiaoliu Zhang; Linden Parkes; Samuel R Chamberlain; Leonardo F Fontenelle; Leah Braganza; George Youssef; Valentina Lorenzetti; Ben J Harrison; Murat Yücel; Chao Suo Journal: Psychiatry Res Neuroimaging Date: 2020-02-11 Impact factor: 2.376
Authors: Christine Lochner; Jean-Paul Fouché; Stefan du Plessis; Bruce Spottiswoode; Soraya Seedat; Naomi Fineberg; Samuel R Chamberlain; Dan J Stein Journal: J Psychiatry Neurosci Date: 2012-05 Impact factor: 6.186
Authors: Katherine C Lopez; Francois Lalonde; Anand Mattai; Benjamin Wade; Liv Clasen; Judith Rapoport; Jay N Giedd Journal: Psychiatry Res Date: 2013-03-01 Impact factor: 3.222
Authors: Jamie D Feusner; Donatello Arienzo; Wei Li; Liang Zhan; Johnson Gadelkarim; Paul M Thompson; Alex D Leow Journal: Psychiatry Res Date: 2013-02-01 Impact factor: 3.222